Effectiveness of National Provider Prescription of PPI Gastroprotection Among Elderly NSAID Users

Abraham, Neena S.; Hartman, Christine; Castillo, Diana; Richardson, Peter; Smalley, Walter
February 2008
American Journal of Gastroenterology;Feb2008, Vol. 103 Issue 2, p323
Academic Journal
OBJECTIVES: Our aim was to quantify the effect of provider adherence on the risk of NSAID-related upper gastrointestinal events (UGIE). METHODS: We identified from national pharmacy records veterans 65 yr prescribed an NSAID, a coxib, or salicylate (>325 mg/day) at any Veterans Affairs (VA) facility (January 1, 2000 to December 31, 2002). Prescription fill data were linked in longitudinal fashion to VA inpatient, outpatient, and death files and merged with demographic, inpatient, outpatient, and provider data from Medicare. Each person-day of follow-up was assessed for exposure to NSAID alone, NSAID+proton pump inhibitor (PPI), coxib, or coxib+PPI. UGIE was defined using our published, validated algorithm. Unadjusted incidence density ratios were calculated for the 365 days following exposure. We assessed risk of UGIE using Cox proportional hazards models, while adjusting for demographics, UGIE risk factors, comorbidity, prescription channeling ( i.e., propensity score), geographic location, and multiple time-dependent pharmacological covariates, including aspirin, steroids, anticoagulants, antiplatelets, statins, and selective serotonin reuptake inhibitors. RESULTS: In our cohort of 481,980 (97.8% male, 85.3% white, mean age 73.9, standard deviation 5.6), a safer strategy was prescribed for 19.8%, and 2,753 UGIE occurred in 220,662 person-years of follow-up. When adjusted for prescription channeling, confounders, and effect modification-associated PPI, risk of UGIE was 1.8 (95% confidence interval [CI] 1.6–2.0) on NSAID alone, 1.8 (95% CI 1.5–2.0) on coxib alone, 1.1 (95% CI 0.7–4.6) on NSAID+PPI, and 1.1 (0.6–5.2) on coxib+PPI. When the analysis was adjusted for cumulative percent time spent on a PPI, risk of UGIE decreased from HR 3.0 (95% CI 2.6–3.7) when a PPI was prescribed 0–20% of the time to 1.1 (95% CI 1.0–1.3) when a PPI was prescribed 80–100% of the time. CONCLUSIONS: Provider adherence to safer NSAID prescribing strategies is associated with fewer UGIE among the elderly. An adherent strategy lowers, but does not eliminate, risk of an NSAID-related UGIE.


Related Articles

  • Effect of Antisecretory Drugs and Nitrates on the Risk of Ulcer Bleeding Associated With Nonsteroidal Anti-Inflammatory Drugs, Antiplatelet Agents, and Anticoagulants. Lanas, Angel; García-Rodríguez, Luis A.; Arroyo, Maria T.; Bujanda, Luis; Gomollón, Fernando; Forné, Montserrat; Aleman, Sofía; Nicolas, David; Feu, Faust; González-Pírez, Antonio; Borda, Ana; Castro, Manuel; Poveda, Maria Jose; Arenas, Juan // American Journal of Gastroenterology;Mar2007, Vol. 102 Issue 3, p507 

    OBJECTIVES: After the withdrawal of some cyclooxygenase-2 (COX-2) selective inhibitors, traditional nonsteroidal anti-inflammatory drug (NSAID) use has increased, but without additional prevention strategies against upper gastrointestinal (GI) complications in many cases. Here, we report the...

  • Overuse of PPIs in Patients at Admission, During Hospitalisation, and at Discharge in a Terciary Spanish Hospital. Ramírez, Elena; Lei, Su H.; Borobia, Alberto M.; Piñana, Enrique; Fudio, Salvador; Muñoz, Raúl; Campos, Armando; Carcas, Antonio J.; Frías, Jesus // Current Clinical Pharmacology;Nov2010, Vol. 5 Issue 4, p288 

    Background: The first generic PPI was introduced in Spain in 2001, and since then their prescriptions have increased steadily by about 200%. Aim: To evaluate the frequency of use and the appropriateness of indications of PPIs in hospitalised patients, and possible factors predicting their use....

  • NSAID/PPI pill only cost effective in high-risk RA patients.  // PharmacoEconomics & Outcomes News;6/23/2012, Issue 656, p13 

    The article discusses a study suggesting the cost-effectiveness of a single-tablet formulation containing nonsteroidal anti-inflammatory drugs and proton-pump inhibitor only for patients at high risk for gastrointestinal complications, by N.L. de Groot and colleagues, presented at the 17th...

  • Peptic Ulcer Disease. Ramakrishnan, Kalyanakrishnan; Salinas, Robert C. // American Family Physician;10/1/2007, Vol. 76 Issue 7, p1005 

    Peptic ulcer disease usually occurs in the stomach and proximal duodenum. The predominant causes in the United States are infection with Helicobacter pylori and use of nonsteroidal anti-inflammatory drugs. Symptoms of peptic ulcer disease include epigastric discomfort (specifically, pain...

  • Prospective, Multivariate Evaluation of CLOtest Performance. Weston, Allan P.; Campbell, Donald R.; Hassanein, Ruth S.; Cherian, Rachel; Dixon, Anita; McGregor, Douglas H. // American Journal of Gastroenterology;Aug1997, Vol. 92 Issue 8, p1310 

    Objectives: To determine prospectively the effect of aspirin, nonsteroidal anti-inflammatory drugs, H2-receptor antagonists, proton pump inhibitors, alcohol intake, race, age, history of Helicobacter pylori eradication attempts, and gastric biopsy location on CLOtest performance....

  • COX-2 inhibitor no safer than naproxen and PPI.  // Journal of Family Practice;Mar2006, Vol. 55 Issue 3, p192 

    The article discusses on the study that determines which is safer between celecoxib and naproxen taken with a proton pump inhibitor in treating patients with previous peptic ulcer in Hong Kong, China. Celecoxib was given to patients who were at high risk for persistent occurrence of peptic ulcer...

  • NSAID-induced peptic ulcers and Helicobacter pylori infection: implications for patient management. Chan, Francis K.L. // Drug Safety;2005, Vol. 28 Issue 4, p287 

    The conflicting data about the influence of Helicobacter pylori infection on the ulcer risk in patients receiving NSAIDs can be accounted for by the heterogeneity of study designs and the diversified host response to H. pylori. Factors that will affect the outcome include the choice of H. pylori...

  • NSAID + PPI easier on the stomach than COX-2 inhibitors.  // Reactions Weekly;7/22/2006, Issue 1111, p4 

    The article presents a study by BMR Spiegel and colleagues which states that the use of the non-steroidal anti-inflammatory drugs (NSAID) and proton pump inhibitor (PPI) combination reduces the risk of dyspeptic symptoms than selective COX-2 inhibitor.

  • The postoperative bleeding rate and its risk factors in patients on antithrombotic therapy who undergo gastric endoscopic submucosal dissection. Toshihisa Takeuchi; Kazuhiro Ota; Satoshi Harada; Shoko Edogawa; Yuichi Kojima; Satoshi Tokioka; Eiji Umegaki; Kazuhide Higuchi // BMC Gastroenterology;2013, Vol. 13 Issue 1, p1 

    Background: There is a lack of consensus regarding the risk of postoperative hemorrhage in patients on antithrombotic therapy who undergo endoscopic submucosal dissection (ESD). We examined postoperative bleeding rates and risk factors for postoperative hemorrhage from post-ESD gastric ulcers in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics